• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

拓展化脓性汗腺炎治疗选择的前沿：比美吉珠单抗的有效贡献。

Expanding the frontiers of therapeutic options in hidradenitis suppurativa: The valid contribution of bimekizumab.

机构信息

Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.

Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.

出版信息

Med. 2024 Oct 11;5(10):1197-1199. doi: 10.1016/j.medj.2024.08.005.

DOI:10.1016/j.medj.2024.08.005
PMID:39395402
Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory cutaneous disorder with a significant negative impact on quality of life. Th17 axis has a central role in the pathogenesis of HS. Kimball et al. demonstrated the efficacy and safety of bimekizumab in two double-blind, placebo-controlled phase 3 studies (BE HEARD I-II), adding a new targeting option to the therapeutic armamentarium of HS..

摘要

化脓性汗腺炎（HS）是一种慢性炎症性皮肤病，对生活质量有重大负面影响。Th17 轴在 HS 的发病机制中起核心作用。Kimball 等人在两项双盲、安慰剂对照的 3 期研究（BE HEARD I-II）中证明了 bimekizumab 的疗效和安全性，为 HS 的治疗手段增添了一种新的靶向选择。

相似文献

1
Expanding the frontiers of therapeutic options in hidradenitis suppurativa: The valid contribution of bimekizumab.拓展化脓性汗腺炎治疗选择的前沿：比美吉珠单抗的有效贡献。
Med. 2024 Oct 11;5(10):1197-1199. doi: 10.1016/j.medj.2024.08.005.
2
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.比美吉珠单抗治疗中重度化脓性汗腺炎患者的疗效和安全性（BE HEARD I 和 BE HEARD II）：两项为期 48 周、随机、双盲、安慰剂对照、多中心 3 期临床试验。
Lancet. 2024 Jun 8;403(10443):2504-2519. doi: 10.1016/S0140-6736(24)00101-6. Epub 2024 May 22.
3
Bimekizumab for the treatment of hidradenitis suppurativa.比美吉珠单抗治疗化脓性汗腺炎。
Immunotherapy. 2024;16(16-17):1005-1013. doi: 10.1080/1750743X.2024.2401308. Epub 2024 Sep 19.
4
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.比美吉珠单抗治疗中重度化脓性汗腺炎的疗效和安全性：一项 2 期、双盲、安慰剂对照随机临床试验。
JAMA Dermatol. 2021 Nov 1;157(11):1279-1288. doi: 10.1001/jamadermatol.2021.2905.
5
Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.基于既往生物制剂暴露情况的中重度化脓性汗腺炎患者使用司库奇尤单抗：来自 III 期 SUNSHINE 和 SUNRISE 研究的疗效和安全性分析。
Br J Dermatol. 2024 May 17;190(6):836-845. doi: 10.1093/bjd/ljae098.
6
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.司库奇尤单抗治疗中重度化脓性汗腺炎（SUNSHINE和SUNRISE研究）：两项相同的多中心、随机、安慰剂对照、双盲3期试验的第16周和第52周结果
Lancet. 2023 Mar 4;401(10378):747-761. doi: 10.1016/S0140-6736(23)00022-3. Epub 2023 Feb 3.
7
Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial.探索 spesolimab 对中重度化脓性汗腺炎患者影响的概念验证研究：一项随机双盲安慰剂对照临床试验。
Br J Dermatol. 2024 Sep 18;191(4):508-518. doi: 10.1093/bjd/ljae144.
8
Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.评估化脓性汗腺炎临床应答（HiSCR）作为化脓性汗腺炎治疗的临床终点的有效性、反应性和有意义性。
Br J Dermatol. 2014 Dec;171(6):1434-42. doi: 10.1111/bjd.13270. Epub 2014 Nov 11.
9
An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa.评估司库奇尤单抗治疗中重度化脓性汗腺炎。
Expert Opin Biol Ther. 2024 Apr;24(4):225-232. doi: 10.1080/14712598.2024.2343112. Epub 2024 Apr 15.
10
The use of biologics and JAK inhibitors in the management of moderate to severe Hidradenitis Suppurativa treatment: a scoping review.生物制剂和 JAK 抑制剂在中重度化脓性汗腺炎治疗中的应用：范围综述。
Arch Dermatol Res. 2024 May 25;316(6):259. doi: 10.1007/s00403-024-03121-x.

引用本文的文献

1
IRAK4 Targeting: A Breakthrough Approach to Combat Hidradenitis Suppurativa.靶向IRAK4：治疗化脓性汗腺炎的突破性方法。
Biologics. 2025 Jun 30;19:387-397. doi: 10.2147/BTT.S525106. eCollection 2025.